Corbus Pharmaceuticals, Inc.

79 articles with Corbus Pharmaceuticals, Inc.

• Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update

  8/8/2018

  Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan

• Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

  6/21/2018

  The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms

• 

  BioSpace Movers and Shakers for Week of June 4th

  6/11/2018

  Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.

• Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors

  6/6/2018

  Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND

• Corbus Pharma Announces Agreement With FDA on Phase IIb Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint

  1/30/2018

  The Company and the FDA agreed that the event rate of pulmonary exacerbation is an acceptable sole primary efficacy endpoint for the clinical development program to support registration of lenabasum for the treatment of CF.

• 

  Tiny Corbus Aims to Have Four Drugs in Mid- to Late-Stage Development by Next Year

  11/21/2017

  In less than four years, Corbus has grown from a tiny startup to a public company with 60 employees and four assets in the clinic.
• 

  This Massachusetts Marijuana Biotech is Betting the Farm on One Single Drug

  10/25/2017

  Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum.

• Corbus Pharmaceuticals Reports Positive Topline Results From Phase 2 Study In Rare Autoimmune Disease Dermatomyositis

  10/19/2017

  Corbus Pharmaceuticals Holdings announced positive topline results from its 16-week Phase II study of safety and efficacy of anabasum in dermatomyositis (“DM”).

• Corbus Pharma Appoints Paris Panayiotopoulos To Its Board Of Directors

  10/19/2017

  Corbus Pharmaceuticals, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors.

• Corbus Announces Presentation Of Three Abstracts At The 2017 North American Cystic Fibrosis Conference

  9/27/2017

• Did Corbus Investors Get Thrown Off By A Red Herring?

  4/11/2017

• Corbus To Commence Single Phase III Study Of Anabasum For Treatment Of Systemic Sclerosis Following Guidance Received From Successful End-Of-Phase II Meeting With FDA

  4/5/2017

• Tiny Massachusetts Phenom Corbus Plunges Despite Reporting Positive Phase II CF Data

  3/30/2017

• The Hype Behind Massachusetts Biotech Corbus' Sole Pipeline Drug

  3/20/2017

• Corbus To Present Gene Expression Data From Recent Phase II Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation And Fibrosis Pathways

  3/8/2017

• Corbus Announces $27.2 Million Registered Direct Offering

  2/28/2017

• Corbus Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation In Alveolar Macrophages From Cystic Fibrosis Patients

  2/24/2017

• Why Corbus' Stock Rocketed 412% Upwards in 2016

  1/17/2017

• Corbus Release: Pharma Receives Orphan Designation For JBT-101 For The Treatment Of Systemic Sclerosis In The European Union

  1/17/2017

• Why Massachusetts’ Corbus Keeps a ‘Remarkably Young Staff’—And How it Plans to Double Headcount

  12/9/2016